Follow The Filings

CAI Caris Life Sciences Inc.

Health Care, filed as CARIS LIFE SCIENCES INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 2 Owners
  • Max 0.7%
  • $209M

Who owns this now

Largest portfolio weights among holders, up to 0.7% (Stanley Druckenmiller, Duquesne Family Office). Not free-float ownership.

  1. Stanley Druckenmiller 0.65%
  2. Philippe Laffont 0.36%

Who owns CAI

Sorted by value, long equity only, as of 2026 Q2.

History
Philippe Laffont, Coatue Management 0.36% Hold 9,819,992 $175M History
Stanley Druckenmiller, Duquesne Family Office 0.65% Hold 1,894,450 $34M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CAI's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CAI insider trades
  • $1.6M bought by 4 insiders
  • $12.4M sold by 2 insiders outside a trading plan
  • $1.7M sold by 1 insider under 10b5-1 plans
  1. John Russel Denton See Remarks
    Sale
    $239K 7,500 shares at $31.82 4.1% of stake
    Traded Sep 22 Filed Sep 23
    ↗
  2. Brian J Brille See Remarks
    Sale
    $12.1M 400,000 shares at $30.33 64% of stake
    Traded Sep 17 Filed Sep 17
    ↗
  3. Jon Halbert Director
    Buy
    $990K 68,000 shares at $14.56 +11% to stake
    Traded May 15 Filed Jul 13
    ↗
  4. Jeff L Vacirca Director
    Buy
    $501K 31,050 shares at $16.15 +167% to stake
    Traded May 11 Filed May 12
    ↗
  5. Luke Thomas Power See Remarks
    Planned sale
    $1.7M 62,250 shares at $26.58 39% of stake
    Traded Dec 11, 2025 Filed Dec 12, 2025
    ↗
  6. David Baxley Spetzler President
    Buy
    $9,540 400 shares at $23.85 +0.1% to stake
    Traded Nov 7, 2025 Filed Nov 10, 2025
    ↗
  7. John Russel Denton See Remarks
    Buy
    $101K 4,184 shares at $24.09 +84% to stake
    Traded Nov 7, 2025 Filed Nov 10, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 21 stock grants, 6 option exercises, 5 share withholdings for taxes, 3 sales to cover taxes, and 2 gifts.

SEC filings

Recent issuer filings from EDGAR, 15 shown.

Filed Form Detail Links
8-K 7.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,1.02,2.03 Filing Doc
10-K Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2025
Revenue $812.03M
Net income -$68.09M
Net margin * -8.4%

Balance sheet

Metric FY2025
Total current assets $997.8M
Total non-current assets * $127.86M
Total assets $1.13B
Total current liabilities $127.14M
Total non-current liabilities * $421.21M
Total equity $577.31M

Cash flow

Metric FY2025
Cash from operations $83.16M
Cash from investing -$16.26M
Cash from financing $664.99M
Net change in cash $732.01M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.